Latest News and Press Releases

NEW YORK, 15 déc. 2025 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

Éti-cel a montré un taux de réponse globale (ORR) de 88 % et un taux de réponse complète (CR) de 63 % (n=8) au niveau de dose actuel chez des patients atteints de LNH en rechute ou réfractaire après...

Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion...

PARIS, 03 déc. 2025 (GLOBE NEWSWIRE) --         Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actionscomposant le capital socialNombre total de droits de...

PARIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma  MT-601 demonstrated 66% objective response rate with 50% complete response in...

Applied StemCell uses TARGATT™ tech to insert a 50 kb multifunctional DNA construct into hiPSCs, enabling development of allogeneic iPSC-based therapies.

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel...

Pluristyx signs key clinical use licenses for its iPSC platform, enabling new regenerative and neurological disease therapies.